QuorumCivic. Hidden in plain sight Get the app
Bill intelligence

Congress designates lung cancer awareness month, spotlights screening gaps

H.Res. 960 — Expressing support for the designation of November 2025 as "National Lung Cancer Awareness Month" and expressing support for early detection and treatment of lung cancer. · Filed by Brendan Boyle (D-PA) · 1 cosponsor · Introduced Dec 18, 2025 · Referred to committee

95%
Transparency
Typical bill: 82%
5/100
Hidden-provision risk
Typical bill: 15/100
Public Health Awareness Resolution

Your members of Congress

Enter a ZIP to see where your representative and both senators stood on this bill.

Looked up on this device — your ZIP is never stored on our servers.

What it does

This resolution designates November 2025 as 'National Lung Cancer Awareness Month' and expresses congressional support for early detection, screening, and treatment of lung cancer. It does not create law or funding; it is a symbolic statement encouraging public awareness, education, and research efforts, with particular attention to disparities affecting Black men, women, veterans, and never-smokers.

Why we flagged it

This is a non-binding commemorative resolution expressing support for lung cancer awareness and early detection. It contains no regulatory, appropriations, or substantive legislative mechanism—only symbolic congressional endorsement of public health goals.

What the text implies

  • Resolution's emphasis on screening access and geographic barriers may indirectly signal congressional interest in funding or policy changes to expand screening infrastructure, though no such mechanism is present in this text.
  • Explicit mention of biomarker testing and 'cutting-edge diagnostics' access disparities may foreshadow future legislative interest in coverage or reimbursement policy for advanced lung cancer diagnostics.

The full analysis lists 3 implications of this text.

Who stands to gain

pharmaceutical companies (immunotherapy and targeted therapy manufacturers); diagnostic imaging and biomarker testing providers; cancer treatment centers and oncology practices

Correlative observation from public records — not evidence of coordination or wrongdoing, and not financial advice.
This page is the record as of today. The app tells you when it changes.
Quorum analysis of the full bill text · 119th Congress · public record